Bladder Cancer

>

Latest News

Enfortumab Vedotin Plus Pembrolizumab May Not Negatively Affect Quality of Life in Metastatic Urothelial Cancer
Enfortumab Vedotin Plus Pembrolizumab May Not Negatively Affect Quality of Life in Metastatic Urothelial Cancer

August 15th 2024

Compared with chemotherapy, enfortumab vedotin plus pembrolizumab improved survival with no detriment to QOL in previously untreated metastatic urothelial cancer.

Olanzapine May Prevent Nausea and Vomiting During Moderately Emetogenic Chemotherapy
Olanzapine May Prevent Nausea and Vomiting During Moderately Emetogenic Chemotherapy

August 12th 2024

Cisplatin-Based Chemotherapy May Affect Hearing in Cancer Survivors
Cisplatin-Based Chemotherapy May Affect Hearing in Cancer Survivors

July 22nd 2024

Perioperative Durvalumab Plus Chemo Shows Promise in Muscle-Invasive Bladder Cancer
Perioperative Durvalumab Plus Chemo Shows Promise in Muscle-Invasive Bladder Cancer

July 10th 2024

Rx Road Map: Enfortumab Vedotin (Padcev)
Rx Road Map: Enfortumab Vedotin (Padcev)

July 2nd 2024

More News

bladder cancer

GU Nurse Talks Exciting Advancements in Bladder Cancer

Brielle Benyon
August 17th 2019

Nurses must stay up to date with the fast-moving world of bladder cancer.

Accelerated Chemo Regimen Extends OS in Neoadjuvant Bladder Cancer Treatment

Accelerated Chemo Regimen Extends OS in Neoadjuvant Bladder Cancer Treatment

Audrey Sternberg
January 29th 2019

Neoadjuvant chemotherapy with dose-dense MVAC extends overall survival compared with other chemo regimens in bladder cancer treated with cystectomy.

Genetic Test Aims to Prevent Over-Treatment, Lower Care Costs in Bladder Cancer

Genetic Test Aims to Prevent Over-Treatment, Lower Care Costs in Bladder Cancer

Jessica Skarzynski
September 29th 2018

A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.

<12
© 2024 MJH Life Sciences

All rights reserved.